检索结果-南通市图书馆

Critically ill patients with cancer: A clinical perspective

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Oncology 2020年第10期11卷 809-835页

作者： Frank Daniel Martos-Benítez Caridad de Dios Soler-Morejón Karla Ximena Lara-Ponce Versis Orama-Requejo DailéBurgos-Aragüez Hilev Larrondo-Muguercia Rahim W Lespoir Intensive Care Unit 8B Hermanos Ameijeiras HospitalHavana 10300Cuba

Cancer patients account for 15%of all admissions to intensive care unit(ICU)and 5%will experience a critical illness resulting in ICU admission.Mortality rates have decreased during the last decades because of new anticancer therapies and advanced organ support methods.Since early critical care and organ support is associated with improved survival,timely identification of the onset of clinical signs indicating critical illness is crucial to avoid delaying.This article focused on relevant and current information on epidemiology,diagnosis,and treatment of the main clinical disorders experienced by critically ill cancer patients.

关键词： Acute respiratory failure Cancer Cardiotoxicity Chemotherapy Critical care Infection Mechanical ventilation Neutropenia Postoperative Sepsis

Design of a Preamplifier Card for the Photomultiplier Tubes of a Gamma Camera

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Physical Science and Application 2018年第1期8卷 46-54页

作者： Jorge Luis Domínguez Martínez The Department of Nuclear Medicine Surgical Clinical Hospital''Hermanos Ameijeiras’’Havana 10300Cuba

The service provided by the GC(Gamma Cameras)in the Nuclear Medicine departments fails because of their breakdown,generally due to the associated electronics and not to the physical detection components.For this reason,it was decided to develop an electronic system that allows the recovery and optimization of disused GC,starting with the design of the preamplifier for a PMT(photomultiplier tube).The circuit was designed and simulated and the list of components necessary for the construction of the preamplifier was generated,as well as the printed circuit board was designed for its assembly.By simulating the preamplifier this worked in linear mode.This determines that the amplitude of the output signal is proportional to the amount of charge delivered by the detector.This card allows an automatic adjustment of the signals of the PMT as do the modern GC.

关键词： Gamma camera nuclear medicine photomultiplier tube preamplifier Cuba

Stratified Cox Regression Analysis of Survival under CIMAvax^(■)EGF Vaccine

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2013年第8期4卷 8-14页

作者： Carmen Viada Gonzalez Jean-Francois Dupuy Martha Fors López Patricia Lorenzo Luaces Camilo Rodríguez Rodríguez Gisela González Marinello Elia Neninger Vinagera Beatriz García Verdecia Bárbara Wilkinson Brito Liana Martínez Pérez Mayelin Troche de la Concepción Tania Crombet-Ramos Center of Molecular Immunology HavanaCuba Institut National des Sciences Appliquées de Rennes RennesFrance National Coordinator Center of Clinical Trial HavanaCuba hermanos ameijeiras hospital HavanaCuba

Background: The Center of Molecular Immunology (CIM) is a center in Cuba devoted to the research, development and manufacturing of biotechnological products. CIMAvax?EGF is a vaccine for the treatment of non-small cell lung cancer patients (NSCL). Purpose: The aim of this work is to evaluate the effects of some potential prognostic factors on the overall survival of patients treated with CIMAvax?EGF vaccine, based on data collected in a phase II and a phase III clinical trials. Methods: The stratified Cox regression model is used to evaluate the effects of these prognostic factors, based on separate analysis for each trial, and on the combined data from both trials. Results: Patients with Performance status 0 or 1, with IV stage of tumor and male under 60 years obtain more benefit in terms of overall survival if they receive CIMAvax?EGF. Conclusions: Vaccinated group has a better performance if patients have a performance status 0 or 1, stage IV and age under 60 years. These prognostic factors influence overall survival in a positive way for those patients that received CIMAvax?EGF.

关键词： Stratified Cox Regression Model Risk Factor Non-Small Lung Cancer Censored Data

CIMAvax^(█)EGF vaccine therapy for non-small cell lung cancer:A weighted log-rank tests-based evaluation

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Modern Chemotherapy 2013年第3期2卷 51-56页

作者： Carmen Viada Gonzalez Jean-Francois Dupuy Martha Fors López Patricia Lorenzo Luaces Gisela González Marinello Elia Neninger Vinagera Beatriz García Verdecia Tania Crombet-Ramos Clinical Trials Department Center of Molecular ImmunologyHavanaCuba National Institute of Applied Sciences of Rennes RennesFrance National Coordinator Center of Clinical Trial HavanaCuba hermanos ameijeiras hospital HavanaCuba

Time-to-event has become one of the primary endpoints of many clinical trials. Comparing treatments and therapies using time-to-event (or “survival”) data requires some care, since survival differences may occur either early or late in the follow-up period, depending on various factors such as the initial potency or the duration of efficacy of the drugs. In this work, we investigate the effect of the CIMAvax?EGF vaccine therapy on the survival of patients with non-small cell lung cancer, using stratified and unstratified weighted log-rank tests. Weighted log-rank tests are designed to identify early and late survival differences between treatments. Using these tests, we conclude that the vaccine is more efficient than the standard therapy among patients less than 60 years of age.

关键词： Log-Rank Test Fleming-Harrington Test Stratified Tests

Safety and Efficacy of Racotumomab-Alum Vaccine as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Clinical Medicine 2014年第14期5卷 844-850页

作者： Eduardo Santiesteban Leslie Perez Sailyn Alfonso Elia Neninger Soraida Acosta Yoana Flores Maurenis Hernandez Carmen Viada Robin García Meylán Cepeda Daymys Estevez Yoisbel Moreno Amparo Macías Celestino Hernández Robau hospital Villa Clara Cuba Center of Molecular Immunology Havana Cuba hermanos ameijeiras hospital Havana Cuba José Ramón López Tabranes hospital Matanzas Cuba National Institute of Oncology and Radiobiology Havana Cuba Saturnino Lora hospital Santiago de Cuba Cuba

Despite extensive clinical research in non-small cell lung cancer (NSCLC), overall survival is still poor. Racotumomab-alum is an anti-idiotypic cancer vaccine that targets NeuGcGM3 tumor associated ganglioside. The aim of this study was to evaluate safety and efficacy of racotumomab-alum in advanced NSCLC patients with progressive disease. This expanded access program included 86 histologically confirmed NSCLC patients, 18 years or older age, with advanced disease and without therapeutic option, with ECOG performance status ≤3, adequate organ functions and signed informed consent. The primary endpoint was overall survival and toxicity was measure assessed treatment-related toxicity according CTCAEv3. The study was approved by ethical review boards of participant institutions. Racotumomab-alum treatment consisted in 5 biweekly intradermal doses (1 mg/mL) during the induction phase of treatment (2 months). The maintenance phase consisted in monthly re-immunizations until unacceptable toxicity or PS worsening. The median overall survival time of all patients treated with racotumomab-alum was 8.96 months. The survival rates at 12 and 24 months were 42.8% and 28.0%, respectively. Patients that completed the induction phase of treatment (five doses or more) reached a median OS of 12.1 months. The most common adverse events were injection site reaction, bone pain, cough and asthenia. Racotumomab-alum cancer vaccine could be considered an effective and safe treatment option as second-line therapy for advanced NSCLC. Further clinical studies should be conducted to confirm this result.

关键词： Non-Small Cell Lung Cancer Cancer Vaccine Second-Line Treatment

Anti-porcine circovirus type 2(PCV2) antibody placental barrier leakage from sow to fetus: impact on the diagnosis of intra-uterine PCV2 infection

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Virologica Sinica 2014年第2期29卷 136-138页

作者： Dipongkor Saha Rubén Del Pozo Sacristán Nicolaas Van Renne Liping Huang Ruben Decaluwe Annelies Michiels Alfonso Lopez Rodriguez Maria José Rodrí-guez Margarita García Durán Ilse Declerk Dominiek Maes Hans J. Nauwynck Laboratory of Virology Faculty of Veterinary Medicine Ghent University Brain Tumor Research Center Department of Molecular Neurosurgery Harvard Medical School and Massachusetts General Hospital Department of Obstetrics Reproduction and Herd Health Faculty of Veterinary Medicine Ghent University Ingenasa Hermanos García Noblejas

Dear Editor,Fetuses develop antibodies when they are infectedwith porcine circovirus type 2(PCV2).At abortion orbirth,both PCV2 and/or anti-PCV2 antibodies can thenbe detected.Finding anti-PCV2 antibodies in aborted fe-tuses or stillborn piglets is generally used as evidence ofan intra-uterine PCV2 infection.However,a recent anal-ysis of fetuses sent in for PCV2 diagnosis and caesare-an-derived,colostrum-deprived pigs revealed that

关键词：猪圆环病毒2型 PCV2 流产胎儿胎盘屏障母猪感染子宫诊断

Pharmacokinetics Evaluation of Nimotuzumab in Combination with Doxorubicin and Cyclophosphamide in Patients with Advanced Breast Cancer

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Journal of Life Sciences 2013年第11期7卷 1123-1133页

作者： Leyanis Rodriguez-Vera Eduardo Fernandez-Sanchez Jorge L. Soriano Noide Batista Maite Lima Joaquin Gonzalez Robin Garcia Carmen Viada Concepcion Peraire Helena Colom Mayra Ramos-Suzarte Laboratory of Pharmacokinetic Department of Pharmacology & Toxicology Institute of Pharmacy & Foods 222 St. and 23 Avenue La Coronela La Lisa University of Havana Havana CP 13600 Cuba Center for Research and Biological Evaluation Institute of Pharmacy & Foods 222 St. and 23 Avenue La Coronela La LisaUniversity of Havana Havana CP 13600 Cuba hermanos ameijeiras hospital San L6zaro Avenue and Street Belascoain Havana Center Havana Cuba Center of Molecular Immunology Street 216 and 15 Atabey Playa Havana Cuba Pharmacy and Pharmaceutical Technology Department School of Pharmacy University of Barcelona Barcelona Spain

EGFr (Epidermal growth factor receptor) overexpression has been detected in many tumors of epithelial origin, specifically in breast cancer and it is often associated with tumor growth advantages and poor prognosis. The nimotuzumab is a genetically engineered humanized MAb (monoclonal antibody) that recognizes an epitope located in the extracellular domain of human EGFr. The aim of this study was to assess the pharmacokinetics of nimotuzumab in patients with locally advanced breast cancer who are receiving neoadyuvant therapy combined with the AC chemotherapy regimen (i. e., 60 mg/m 2 of Doxorubicin and 600 mg/m 2 of Cyclophosphamide in 4 cycles every 21 days). A single center, non-controlled, open Phase I clinical trial, with histopathological diagnosis of locally advanced stage III breast cancer, was conducted in 12 female patients. Three patients were enrolled at each of the following fixed dose levels 50, 100, 200 and 400 mg/week. Multiple intermittent short-term intravenous infusions of nimotuzumab were administered weekly, except on weeks 1 and 10, when blood samples were drawn for pharmacokinetic assessments. Nimotuzumab showed dose-dependent kinetics. No anti-idiotypic response against nimotuzumab was detected in blood samples of participants. There was not interaction between the administration of nimotuzumab and chemotherapy at the dose levels studied. The optimal biological doses ranging were estimated to be 200 mg/weekly to 400 mg/weekly.

关键词：药代动力学环磷酰胺乳腺癌单抗晚期阿霉素表皮生长因子受体治疗

HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2014年第1期20卷 148-162页

作者： Yalena Amador-Caizares Gillian Martínez-Donato Liz lvarez-Lajonchere Claudia Vasallo Mariacarla Dausá Daylen Aguilar-Noriega Carmen Valenzuela Ivette Raíces Jean Dubuisson Czeslaw Wychowski Zurina Cinza-Estévez Marlén Castellanos Magdalys Núez Anny Armas Yaimé González Ismariley Revé Ivis Guerra ngel Pérez Aguiar Santiago Dueas-Carrera Centro de Ingeniería Genética y Biotecnología Playa 10600HavanaCuba Center for Infection and Immunity of Lille (CIIL) Inserm U1019CNRS UMR8204Institut Pasteur de LilleUniv Lille Nord de FranceF-59000 LilleFrance Instituto de Gastroenterología Vedado 10400HavanaCuba hospital Clínico Quirúrgico "hermanos Amejeiras" Havana 10200Cuba Centro de Inmunoensayos Havana 11300Cuba

AIM:To analyze hepatitis C virus(HCV)-specific immune responses in chronically infected patients under triple therapy with interferon-α(IFN-α)plus ribavirin and CIGB-230.METHODS:CIGB-230 was administered in different schedules with respect to IFN-αplus ribavirin therapy.Paired serum and peripheral blood mononuclear cells(PBMC)samples from baseline and end of treatment were analyzed.The HCV-specific humoral response was tested by enzyme-linked immunosorbent assay,neutralizing antibodies were evaluated by cell culture HCV neutralization assays,PBMC proliferation was assayed by carboxyfluorescein succinimidyl ester staining and IFN-γsecretion was assessed by enzyme-linked immunospot.Data on virological and histological response and their association with immune variables are also provided.RESULTS:From week 12 to week 48,all groups of patients showed a significant reduction in mean leukocyte counts.Statistically significant reductions in antibody titers were frequent,but only individuals immunized with CIGB-230 as early add-on treatment sustained the core-IgG response,and the neutralizing antibody response was enhanced only in patients receiving CIGB-230.Cell-mediated immune responses also tended to decline,but significant reductions in IFN-γsecretion and total absence of core-specific lymphoproliferation were exclusive of the control group.Only CIGB-230-immunized individuals showed de novo induced lymphoproliferative responses against the structural antigens.Importantly,it was demonstrated that thequality of the CIGB-230-induced immune response depended on the number of doses and timing of administration in relation to the antiviral therapy.Specifically,the administration of 6 doses of CIGB-230 as late addon to therapy increased the neutralizing antibody activity and the de novo core-specific IFN-γsecretion,both of which were associated with the sustained virological response.CONCLUSION:CIGB-230,combined with IFN-α-based therapy,modifies the immune response in chronic patients.The study provides evidence for the des

关键词： Clinical trial DNA vaccine Enzyme-linked immunospo